Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02938013 · ClinicalTrials.gov registry record · Phase 4
deLIVER: Direct Acting Antiviral Effects on the Liver
A Phase 4 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT02938013: Completed Phase 4 study, sponsored by Johns Hopkins University.
NCT02938013 is a Phase 4 study that has completed, run by Johns Hopkins University. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02938013, a Phase 4 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
Open-label, partially-randomized plasma and liver sampling study to assess hepatitis C virus (HCV) kinetics during treatment with two (Sofosbuvir/Velpatasvir) or three (Sofosbuvir/Velpatasvir/Voxilaprevir) direct acting antivirals (DAAs)
Interventions
- DRUG Sofosbuvir/Velpatasvir (SOF/VEL)
- DRUG Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-01 |
| Est. Completion | 2020-09-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02938013
The ClinicalTrials.gov registry entry for NCT02938013 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sofosbuvir/Velpatasvir (SOF/VEL) is the first listed.
NCT02938013 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02938013 about?
NCT02938013 is a clinical study titled "deLIVER: Direct Acting Antiviral Effects on the Liver". Open-label, partially-randomized plasma and liver sampling study to assess hepatitis C virus (HCV) kinetics during treatment with two (Sofosbuvir/Velpatasvir) or three (Sofosbuvir/Velpatasvir/Voxilaprevir) direct acting antivirals (DAAs)
What is the current status of trial NCT02938013?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2017-01. Estimated completion is 2020-09-30.
What interventions are being tested in trial NCT02938013?
The interventions under investigation include: Sofosbuvir/Velpatasvir (SOF/VEL) (DRUG), Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX] (DRUG).
Who is sponsoring clinical trial NCT02938013?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.